Xponance LLC Purchases 3,282 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Xponance LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,773 shares of the pharmaceutical company’s stock after acquiring an additional 3,282 shares during the quarter. Xponance LLC’s holdings in Vertex Pharmaceuticals were worth $29,819,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Colonial Trust Co SC raised its holdings in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 38 shares during the period. Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter worth $29,000. IMG Wealth Management Inc. grew its position in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 50 shares during the last quarter. Ares Financial Consulting LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter worth $33,000. Finally, Archer Investment Corp grew its position in Vertex Pharmaceuticals by 89.7% in the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 6,988 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total value of $3,144,600.00. Following the transaction, the chief marketing officer directly owned 26,088 shares in the company, valued at $11,739,600. The trade was a 21.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares in the company, valued at approximately $8,810,239.58. This trade represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,133 shares of company stock worth $4,973,106 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex announced new data on CASGEVY, including the first European presentation of results in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia, with outcomes consistent with the therapy’s established profile in older patients. The company also disclosed additional global regulatory submissions, which could support future sales growth. Article: Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
• Positive Sentiment: Investor sentiment improved after articles highlighted Vertex as a stock Wall Street continues to favor despite a “death cross” technical signal, suggesting some traders see the company’s long-term fundamentals as strong enough to ignore the bearish chart pattern. Article: The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex
• Neutral Sentiment: Vertex’s share price recently rebounded after a prior pullback, with market wrap-up pieces noting it rose above the broader market and closed at $444.41 after a 2% gain. Article: Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
• Neutral Sentiment: Vertex also presented at the Goldman Sachs Global Healthcare Conference, which may have helped keep the stock in focus, but no major new financial guidance was disclosed in the available summary. Article: Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Erste Group Bank slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small but negative read-through for future earnings expectations. Article: Vertex Pharmaceuticals Incorporated (VRTX) – Earnings Estimate Cut

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Bank of America raised their price target on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 30th. Scotiabank raised their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Truist Financial assumed coverage on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 27th. They issued a “buy” rating and a $542.00 price target on the stock. Finally, Sanford C. Bernstein decreased their price target on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $555.91.

Vertex Pharmaceuticals Stock Up 2.1%

NASDAQ VRTX opened at $445.04 on Friday. The stock has a market cap of $112.95 billion, a P/E ratio of 26.40, a PEG ratio of 1.86 and a beta of 0.30. The company’s 50-day simple moving average is $437.19 and its 200 day simple moving average is $452.38. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.06 earnings per share. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.